Impact of pneumococcal conjugate vaccines on hospitalizations for pneumonia in the United States
- PMID: 30759352
- PMCID: PMC6443450
- DOI: 10.1080/14760584.2019.1582337
Impact of pneumococcal conjugate vaccines on hospitalizations for pneumonia in the United States
Abstract
Pneumonia is one of the leading causes of morbidity and mortality among children and older adults. Pneumococcal conjugate vaccines (PCVs) were introduced into the US routine infant vaccination schedule leading to substantial reductions of invasive pneumococcal diseases (IPD). PCV introduction also led to reductions in all-cause pneumonia among US children, though the indirect impact of PCVs on pneumonia in adults is difficult to quantify, especially due to the recent US recommendation for direct PCV use in older adults. Areas covered: We described the existing evidence for both the direct and indirect impact of PCVs on pneumonia among children and adults in the US since PCV introduction. Expert commentary: The introduction of PCVs into the US routine infant vaccination schedule led to important reductions in the burden of IPD and non-invasive pneumonia among vaccinated and unvaccinated populations. The impact of direct vaccination of older adults in the US since 2014, though difficult to quantify, is currently being evaluated. As pneumonia remains one of the leading causes of morbidity and mortality in the US, future evaluations of the direct and indirect effects of current and expanded valency PCVs in the US population are needed.
Keywords: Pneumococcal conjugate vaccines; pneumococcal disease; pneumonia; routine infant vaccination.
Conflict of interest statement
Disclosures
ADW and MRG have no financial disclosures or conflicts of interest to report. CGG has received consulting fees from Pfizer, Sanofi and Merck and received research support from Sanofi-Pasteur, Campbell Alliance, the Centers for Disease Control and Prevention, National Institutes of Health, The Food and Drug Administration, and the Agency for Healthcare Research and Quality. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
Similar articles
-
Herd effects of child vaccination with pneumococcal conjugate vaccine against pneumococcal non-invasive community-acquired pneumonia: What is the evidence?Hum Vaccin Immunother. 2017 May 4;13(5):1177-1181. doi: 10.1080/21645515.2016.1264548. Epub 2016 Dec 12. Hum Vaccin Immunother. 2017. PMID: 27937061 Free PMC article. Review.
-
The potential impact of pneumococcal conjugate vaccine in Africa: Considerations and early lessons learned from the South African experience.Hum Vaccin Immunother. 2016;12(2):314-25. doi: 10.1080/21645515.2015.1084450. Hum Vaccin Immunother. 2016. PMID: 26317537 Free PMC article. Review.
-
Impact of pneumococcal conjugate vaccination of infants on pneumonia and influenza hospitalization and mortality in all age groups in the United States.mBio. 2011 Jan 25;2(1):e00309-10. doi: 10.1128/mBio.00309-10. mBio. 2011. PMID: 21264063 Free PMC article.
-
Estimated Population-Level Impact of Pneumococcal Conjugate Vaccines Against All-Cause Pneumonia Mortality Among Unvaccinated in 5 Latin American Countries.J Infect Dis. 2024 Oct 16;230(4):e768-e776. doi: 10.1093/infdis/jiae144. J Infect Dis. 2024. PMID: 38502711 Free PMC article.
-
Pneumonia hospitalisations in Scotland following the introduction of pneumococcal conjugate vaccination in young children.BMC Infect Dis. 2016 Aug 9;16:390. doi: 10.1186/s12879-016-1693-x. BMC Infect Dis. 2016. PMID: 27506837 Free PMC article.
Cited by
-
To Boost or Not to Boost? Lessons from the Australian Pneumococcal Conjugate Vaccination Program.Clin Infect Dis. 2020 Jun 10;70(12):2616-2618. doi: 10.1093/cid/ciz735. Clin Infect Dis. 2020. PMID: 31388668 Free PMC article. No abstract available.
-
PfaSTer: a machine learning-powered serotype caller for Streptococcus pneumoniae genomes.Microb Genom. 2023 Jun;9(6):mgen001033. doi: 10.1099/mgen.0.001033. Microb Genom. 2023. PMID: 37279053 Free PMC article.
-
Intervention for the Increase in the Uptake of Pneumococcal Vaccination Among Older Patients: A Systematic Review and Meta-Analysis.Cureus. 2025 Apr 20;17(4):e82615. doi: 10.7759/cureus.82615. eCollection 2025 Apr. Cureus. 2025. PMID: 40400798 Free PMC article. Review.
-
Influence of Older Age and Other Risk Factors on Pneumonia Hospitalization in Switzerland in the Pneumococcal Vaccine Era.Front Med (Lausanne). 2019 Dec 5;6:286. doi: 10.3389/fmed.2019.00286. eCollection 2019. Front Med (Lausanne). 2019. PMID: 31867337 Free PMC article.
-
20‑Valent Pneumococcal Conjugate Vaccine: Pediatric First Approval.Paediatr Drugs. 2023 Sep;25(5):613-619. doi: 10.1007/s40272-023-00584-9. Paediatr Drugs. 2023. PMID: 37440125 Review.
References
-
- File TM Jr., Tan JS. Pneumonia in older adults: reversing the trend. Jama, 294(21), 2760–2763 (2005). - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials